

Basingstoke, Southampton and Winchester

District Prescribing Committee (DPC)

Recommendations of the meeting of 12th December 2017

Supported or limited support e.g. Specialist recommendation

- **Eslicarbazepine (Zebinix®) tabs** – these are supported for use following specialist recommendation in patients with epilepsy who have contraindications or unacceptable adverse effects with carbamazepine or oxcarbazepine. Consider adding to formularies as ‘Amber’.
- **Beclometasone/Formoterol/Glycopyrronium MDI inh (Trimbow®)** – This triple inhaler is supported for use for maintenance treatment of moderate to severe COPD in patients not adequately controlled by combination of ICS and LABA. The COPD guidelines will be updated to reflect the availability and place in therapy of the triple combination inhaler.
- **Colesevelam (Cholestagel®) tabs**– these are supported for use following specialist recommendation as second line treatment to colestyramine for treatment of bile acid malabsorption-associated diarrhoea (‘off-label’ indication). Consider adding to formularies as ‘Amber’.

Not supported

- **Safinamide (Xadago®) tablets** – Based on the lack of clinical evidence of efficacy or superiority in adverse effect profile, the committee did not support the use of safinamide for the treatment of Parkinson’s disease in mid- to late-stage fluctuating patients failing to respond to, or experiencing adverse effects with other treatments, e.g. rasagiline, selegiline, entacapone, with the aim of delaying progression to more invasive treatments, e.g. apomorphine, levodopa/carbidopa intestinal gel, deep brain stimulation.
- **Lidocaine/Prilocaine (Fortacin®) spray** - for the treatment of premature ejaculation. The DPC has not evaluated this product, but it is not currently supported for use locally on the NHS.
- **Naltrexone–bupropion (Mysimba®) MR tabs** – following NICE TA494 the use of naltrexone-bupropion tablets is not supported for managing weight and obesity in adults alongside a reduced-calorie diet and increased physical activity.
- Following the publication of the national commissioning guidance on items which should not be routinely prescribed in primary care, the DPC agreed that no new patients should be initiated on **lutein and antioxidant preparations (including Viteyes)** for the prevention of age-related macular degeneration.

Other Information and formulary updates

- **Enoxaparin Biosimilar (Inhixa®)** – a factsheet for primary healthcare professionals, which contains prescribing and administration information, is now available on the West Hampshire CCG website.
 - **Pivmecillinam (Selexid®)** for the treatment of urinary tract infections. This is now recommended as ‘Amber’ in line with the updated guidelines for antibiotic prescribing in the community.
 - **Xultophy (Liraglutide and Insulin degludec)** - This should now be considered as Amber.
 - **Magnesium Glycerophosphate** - There are now two licensed products available, MagnaPhos® oral solution 5mmol/5ml or 121.25mg/5ml and Neomag tablets 4mmol /tablet or 97mg of magnesium.
 - **Ciclosporin for rheumatoid arthritis, psoriasis, atopic dermatitis Shared Care Guidelines** – This guideline has been approved and will be uploaded to the West Hampshire CCG website.
 - **Southern Health Guidance** - Updated guidance on Depot injections and medicines guidelines for people with learning disabilities will be added to the Southern Health website.
- Guidance documents are available at: <http://www.westhampshireccg.nhs.uk/downloads/categories/medicines/guidance>